The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
PRIMO 2023 | Will neoadjuvant targeted therapies play a role in NSCLC?
Jorge Nieva, MD, University of California, San Francisco, CA, provides an overview of the potential role of targeted therapies in the neoadjuvant setting for non-small cell lung cancer (NSCLC). Trials such as the LCMC4 trial (NCT04712877) will evaluate targeted therapies, and Dr Nieva additionally highlights anecdotal evidence supporting the use of neoadjuvant targeted therapies. However, whether they will improve cure rate and their role in stage II/III lung cancer, remain unelucidated. This interview took place at the Practical Recommendations in Immuno and Molecular Oncology (PRIMO) 2023 Congress in Honolulu, HI.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
